Acute Coronary Syndrome

Clinical trial evaluating rNAPc2 as heparin replacement enrollment initiated

Published in Hematology Week, September 19th, 2005

Nuvelo Inc. (NUVO) announced enrollment of the first patient in a phase 2 "proof of concept" clinical trial evaluating rNAPc2 (recombinant nematode anticoagulant protein c2) as a potential replacement for heparin in patients being treated for acute coronary syndromes (ACS).

This phase 2 trial, also known as Anticoagulation with rNAPc2 To Help Eliminate MACE (ANTHEM/TIMI) 32, is a single-arm, open-label study that is evaluating the efficacy and safety of rNAPc2 by reducing the dose of, and ultimately replacing, unfractionated heparin in patients being treated for ACS.

The study will include from 50 to 100 patients and is being conducted in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hematology Week

Source: Hematology Week (2005-09-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry